EMA400 clinical trials
Also written EMA401.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses EMA400 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- EMA401
- 2
Studies by the year they started
4 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Novartis Pharmaceuticals (2) · Spinifex Pharmaceuticals Pty Ltd (2)
Studies
Open first, then newest update. How each study uses EMA400 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)TerminatedPhase 2Novartis PharmaceuticalsNCT03297294Written as EMA401
- Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)TerminatedPhase 2Novartis PharmaceuticalsNCT03094195Written as EMA401
- Clinical Trial Designed to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic NeuropathyWithdrawnPhase 2Spinifex Pharmaceuticals Pty LtdNCT02435199Written as EMA401 600mg
- Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHNWithdrawnPhase 2Spinifex Pharmaceuticals Pty LtdNCT02426411Written as EMA401 200 mg